Arrowhead Research Corp. (NASDAQ:ARWR) Director Douglas B. Given sold 12,000 shares of the business’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $6.72, for a total transaction of $80,640.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of Arrowhead Research Corp. (NASDAQ:ARWR) opened at 6.65 on Wednesday. The company’s market cap is $403.99 million. Arrowhead Research Corp. has a 1-year low of $3.07 and a 1-year high of $8.22. The company has a 50-day moving average of $7.11 and a 200-day moving average of $6.18.

Arrowhead Research Corp. (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Arrowhead Research Corp. had a negative net margin of 48,980.81% and a negative return on equity of 100.50%. The business earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. The firm’s revenue was down 68.0% on a year-over-year basis. Equities analysts forecast that Arrowhead Research Corp. will post ($1.31) EPS for the current year.

Several research firms have recently issued reports on ARWR. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price objective on shares of Arrowhead Research Corp. in a report on Thursday, September 29th. Piper Jaffray Cos. dropped their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, August 10th. Chardan Capital set a $10.00 price objective on shares of Arrowhead Research Corp. and gave the stock a “buy” rating in a report on Thursday, September 29th. Finally, William Blair began coverage on shares of Arrowhead Research Corp. in a report on Friday, August 19th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Research Corp. has an average rating of “Buy” and a consensus price target of $10.11.

A number of hedge funds have recently made changes to their positions in the stock. Moors & Cabot Inc. boosted its stake in shares of Arrowhead Research Corp. by 0.6% in the second quarter. Moors & Cabot Inc. now owns 36,270 shares of the company’s stock worth $190,000 after buying an additional 200 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Arrowhead Research Corp. by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock worth $675,000 after buying an additional 852 shares in the last quarter. Falcon Point Capital LLC boosted its stake in shares of Arrowhead Research Corp. by 12.5% in the second quarter. Falcon Point Capital LLC now owns 49,147 shares of the company’s stock worth $261,000 after buying an additional 5,458 shares in the last quarter. California Public Employees Retirement System purchased a new stake in shares of Arrowhead Research Corp. during the second quarter worth approximately $1,462,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Arrowhead Research Corp. by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 290,559 shares of the company’s stock worth $1,547,000 after buying an additional 19,376 shares in the last quarter. Hedge funds and other institutional investors own 33.97% of the company’s stock.

About Arrowhead Research Corp.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

5 Day Chart for NASDAQ:ARWR

Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.